New imaging agent could help doctors see which lung tumors are still growing
NCT ID NCT07619599
First seen Jun 05, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This early-phase trial is testing a new PET imaging agent called 64Cu-DOTA-pembrolizumab in 6 people with stage IV non-small cell lung cancer who are already on pembrolizumab and need radiation for some growing tumors. The goal is to see if the scan can safely tell the difference between tumors that are still growing and those that are stable. If it works, it could help doctors decide which spots need radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
64Cu-DOTA-pembrolizumab (a radioactive imaging agent)
What this could lead to
If successful, this could help doctors better tell which tumors are still growing during treatment, improving decisions about radiation therapy.
What could go wrong
This is a very early, small pilot study with only 6 participants, so results may not apply widely. The imaging agent may not clearly distinguish tumor types or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.